Xencor, Inc. focuses on advancing a robust pipeline of bispecific antibodies and other protein therapeutics targeting significant unmet medical needs in oncology and immunology. The company's core technology, the XmAb platform, enables precise modifications to the Fc domain of antibodies, allowing for the development of highly selective immune modulators and targeted therapies. Xencor operates a hybrid business model, advancing its wholly-owned internal candidates—such as XmAb819 for renal cell carcinoma and XmAb942 for inflammatory bowel disease—while also generating revenue through strategic licensing partnerships and royalties from larger pharmaceutical companies. The company outsources its GMP manufacturing to specialized contract development and manufacturing organizations (CDMOs), maintaining a capital-efficient approach to clinical development.
